A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two PF-07940367 Film-Coated Tablet Formulations Administered as 150 mg Under Fasted Conditions in Healthy Participants zhoum55 Tue, 11/03/2026 - 03:21 Osivelotor (PF-07940367) Osivelotor (PF-07940367) PHASE I Mon, 01/15/2024 - 12:00 Tue, 05/07/2024 - 12:00 NCT06190561 C5351008 Public Disclosure Synopsis.pdf (101.85 KB) N https://clinicaltrials.gov/study/NCT06190561?term=C5351008&viewType=Card&rank=1 C5351008